{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:17:30Z","timestamp":1793042250773,"version":"4.5.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Recent evidence has reported significant improvement in clinical profile, quality of life, and prognosis of heart failure subjects with iron replacement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>This study aimed to determine the safety and outcome of parenteral iron replacement among heart failure subjects in Nigeria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>\n                      A randomized interventional study was done at the Cardiology Clinic of LAUTECH Teaching Hospital, Ogbomoso, Nigeria. One hundred and forty subjects with heart failure were recruited. Iron deficiency and anemia were determined according to standardized criteria. Parenteral iron dextran was administered to a block randomized group of 30 of those identified with iron deficiency and compared with controls. The primary outcome was the six minutes' walk test (6 MWT) after 8 weeks while the Kansas City Cardiomyopathy Questionnaire (KCCQ) score was used to assess the quality of life as a secondary outcome. Statistical analysis was done with the SPSS 20.0.\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value &lt;0.05 was taken as statistically significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Iron deficiency was present in 84 (60.0%) of all study participants. Iron dextran was fairly tolerated with mild to moderate adverse reactions reported in 7 (23.3%) subjects who had an iron infusion. Improvement in the 6 MWT distance (390.1 \u00b1 92.6 vs. 156.9 \u00b1 72.5 meters,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05) and the KCCQ score (84.5 \u00b1 3.7 vs. 64.2 \u00b1 12.5%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05) among iron-deficient heart failure subjects who received iron dextran was significantly higher than those who did not receive the iron replacement. Functional classification according to the New York Heart Association (NYHA) profile and heart rate were also much improved after the iron replacement than those who did not receive it.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Parenteral iron dextran therapy was fairly tolerated among heart failure subjects. Iron replacement is associated with improved quality of life, better temporal clinical profile, and functional classification among Nigerians with heart failure. Iron replacement therapy can be an additional therapeutic option in heart failure management among Africans to improve prognosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/njcp.njcp_387_19","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T02:48:05Z","timestamp":1692586085000},"page":"21-27","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Iron Deficiency Anemia in Nigerians with Heart Failure (IDAN-HF)"],"prefix":"10.4103","volume":"24","author":[{"given":"AA","family":"Akintunde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"OM","family":"Akinlade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BE","family":"Egbewale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"OG","family":"Opadijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20240907","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/heart.83.5.596","article-title":"Epidemiology, aetiology, and prognosis of heart failure","volume":"83","author":"McMurray","year":"2000","journal-title":"Heart"},{"key":"R2-4-20240907","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1136\/heartjnl-2013-303592","article-title":"Recent advances in the epidemiology, pathogenesis and prognosis of acute heart failure and cardiomyopathy in Africa","volume":"99","author":"Sliwa","year":"2013","journal-title":"Heart"},{"key":"R3-4-20240907","first-page":"349","article-title":"Pattern of heart failure in Abuja, Nigeria: An echocardiographic study","volume":"20","author":"Ojji","year":"2009","journal-title":"Cardiovasc J Afr"},{"key":"R4-4-20240907","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0140-6736(08)60417-1","article-title":"Spectrum of heart disease and risk factors in a black urban population in South Africa (The heart of Soweto study): A cohort study","volume":"371","author":"Sliwa","year":"2008","journal-title":"Lancet"},{"key":"R5-4-20240907","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.jacc.2007.07.030","article-title":"Heart failure in sub-saharan Africa: Time for action","volume":"50","author":"Damasceno","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R6-4-20240907","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1001\/archinternmed.2012.3310","article-title":"The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries: Results of the sub-saharan Africa survey of heart failure","volume":"172","author":"Damasceno","year":"2012","journal-title":"Arch Int Med"},{"key":"R7-4-20240907","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrcardio.2014.147","article-title":"Heart failure: Long term iron therapy is beneficial in patients with heart failure","volume":"11","author":"Duarte","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"R8-4-20240907","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/CRD.0b013e3181e71150","article-title":"Treatment of anemia in heart failure: Potential risks and benefits of intravenous iron therapy in cardiovascular disease","volume":"18","author":"Jelani","year":"2010","journal-title":"Cardiol Rev"},{"key":"R9-4-20240907","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.hfc.2010.03.004","article-title":"Future directions in management of anaemia in heart failure","volume":"6","author":"Agarwal","year":"2010","journal-title":"Heart Fail Clin"},{"key":"R10-4-20240907","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/nrcardio.2011.77","article-title":"Anaemia and iron deficiency in heart failure: Mechanisms and therapeutic approaches","volume":"8","author":"van Veldhuisen","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"R11-4-20240907","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jacc.2007.09.036","article-title":"Effect of intravenous iron sucrose on exercise tolerance in anemic and non-anemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: A randomized controlled observer blinded trial","volume":"51","author":"Okonkwo","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R12-4-20240907","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMra041809","article-title":"Anaemia of chronic disease","volume":"352","author":"Weiss","year":"2005","journal-title":"N Engl J Med"},{"key":"R13-4-20240907","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1600-0609.1992.tb01801.x","article-title":"Association between the activation of macrophages, changes of iron metabolism and the degree of anemia in patients with malignant disorders","volume":"48","author":"Denz","year":"1992","journal-title":"Eur J Haematol"},{"key":"R14-4-20240907","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.jacc.2011.04.040","article-title":"Disordered iron homeostasis in chronic heart failure: Prevalence, predictors and relation to anaemia, exercise capacity and survival","volume":"58","author":"Okonkwo","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R15-4-20240907","doi-asserted-by":"crossref","first-page":"12155","DOI":"10.1021\/ja809983g","article-title":"Peroxo-type intermediates in class I ribonucleotide reductase and related binuclear non-heme iron enzymes","volume":"131","author":"Jensen","year":"2009","journal-title":"J Am Chem Soc"},{"key":"R16-4-20240907","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/jn\/119.1.40","article-title":"Effects of different degrees of iron deficiency on cytochrome P450 complex and pentose phosphate pathway dehydrogenases in the rat","volume":"119","author":"Dhur","year":"1989","journal-title":"J Nutr"},{"key":"R17-4-20240907","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S0002-9149(96)00697-2","article-title":"Serum iron level, coronary artery disease, and all-cause mortality in older men and women","volume":"79","author":"Corti","year":"1997","journal-title":"Am J Cardiol"},{"key":"R18-4-20240907","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2215\/CJN.03980808","article-title":"Association of markers of iron stores with outcomes in patients with non-dialysis-dependent chronic kidney disease","volume":"4","author":"Kovesdy","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R19-4-20240907","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.archger.2003.12.005","article-title":"Distortion of iron status indices by acute inflammation in older hospitalized patients","volume":"39","author":"Cunietti","year":"2004","journal-title":"Arch Gerontol Geriatr"},{"key":"R20-4-20240907","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1016\/j.ijcard.2013.06.045","article-title":"Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carbozymaltose : FAIR-HF sub-analysis","volume":"168","author":"Gutzwiller","year":"2013","journal-title":"Int J Cardiol"},{"key":"R21-4-20240907","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"key":"R22-4-20240907","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.3390\/nu5093730","article-title":"Iron deficiency in heart failure: A practical guide","volume":"5","author":"Ebner","year":"2013","journal-title":"Nutrients"},{"key":"R23-4-20240907","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/eurjhf\/hft099","article-title":"Intravenous ferric carboxymaltose in iron-defficient chronic heart failure patients with and without anaemia: A sub-analysis of the FAIR-HF trial","volume":"15","author":"Filippatos","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"R24-4-20240907","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ejhf.823","article-title":"Effects of ferric carboxymaltose on hospitalizations and mortality rates in iron-deficient heart failure patients: An individual patient data meta-analysis","volume":"20","author":"Anker","year":"2018","journal-title":"Eur J Hear Fail"},{"key":"R25-4-20240907","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.ihj.2017.10.009","article-title":"Effect of ferric carboxymaltose on hospitalization and mortality outcomes in chronic heart failure: A meta-analysis","volume":"69","author":"Dalal","year":"2017","journal-title":"Indian Heart J"},{"key":"R27-4-20240907","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/ejhf.139","article-title":"High prevalence of iron deficiency in patients with acute decompensated heart failure","volume":"16","author":"Cohen-Solal","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"R28-4-20240907","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ahj.2013.01.017","article-title":"Iron deficiency in chronic heart failure: An international pooled analysis","volume":"165","author":"Klip","year":"2013","journal-title":"Am Heart J"},{"key":"R29-4-20240907","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jacc.2011.11.040","article-title":"Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction","volume":"59","author":"Ather","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R30-4-20240907","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.cardfail.2004.01.004","article-title":"Anemia in chronic heart failure: Pathogenetic mechanisms","volume":"10","author":"Okonko","year":"2004","journal-title":"J Card Fail"},{"key":"R31-4-20240907","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.jacc.2011.04.040","article-title":"Disordered iron homeostasis in chronic heart failure: Prevalence, predictors, and relation to anemia, exercise capacity, and survival","volume":"58","author":"Okonko","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R32-4-20240907","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.cardfail.2011.08.003","article-title":"Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure","volume":"17","author":"Jankowska","year":"2011","journal-title":"J Cardiac Fail"},{"key":"R33-4-20240907","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jacc.2012.08.1021","article-title":"Mitochondria as a therapeutic target in heart failure","volume":"61","author":"Bayeva","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R34-4-20240907","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jacc.2006.07.015","article-title":"Intravenous iron alone for the treatment of anemia in patients with chronic heart failure","volume":"48","author":"Bolger","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R35-4-20240907","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1093\/eurheartj\/ehm328","article-title":"Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia","volume":"28","author":"Van Veldhuisen","year":"2007","journal-title":"Eur Heart J"},{"key":"R36-4-20240907","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/HJR.0b013e3282f849d0","article-title":"Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure","volume":"15","author":"Kourea","year":"2008","journal-title":"Eur J Cardiovasc Prevent Rehab"}],"container-title":["Nigerian Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_387_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:14:39Z","timestamp":1787166879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_387_19"}},"subtitle":["Therapeutic Efficacy of Iron Replacement An Interventional Study"],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/njcp.njcp_387_19","relation":{},"ISSN":["1119-3077"],"issn-type":[{"value":"1119-3077","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}